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Abstract
Invasive aspergillosis (IA) is a live-threatening opportunistic infection that is best described in haematological patients with prolonged
neutropenia or graft-versus-host disease. Data on IA in non-neutropenic patients are limited. The aim of this study was to establish the
incidence, disease manifestations and outcome of IA in non-neutropenic patients diagnosed in ﬁve Swiss university hospitals during a 2-
year period. Case identiﬁcation was based on a comprehensive screening of hospital records. All cases of proven and probable IA were
retrospectively analysed. Sixty-seven patients were analysed (median age 60 years; 76% male). Sixty-three per cent of cases were inva-
sive pulmonary aspergillosis (IPA), and 17% of these were disseminated aspergillosis. The incidence of IPA was 1.2/10 000 admissions.
Six of ten cases of extrapulmonary IA affected the brain. There were six cases of invasive rhinosinusitis, six cases of chronic pulmonary
aspergillosis, and cases three of subacute pulmonary aspergillosis. The most frequent underlying condition of IA was corticosteroid
treatment (57%), followed by chronic lung disease (48%), and intensive-care unit stays (43%). In 38% of patients with IPA, the diagnosis
was established at autopsy. Old age was the only risk factor for post-mortem diagnosis, whereas previous solid organ transplantation
and chronic lung disease were associated with lower odds of post-mortem diagnosis. The mortality rate was 57%.
Keywords: Corticosteroid treatment, critically ill, invasive aspergillosis, non-neutropenic hosts, opportunistic infection
Original Submission: 19 September 2010; Accepted: 27 September 2010
Editor: E. Roilides
Article published online: 15 October 2010
Clin Microbiol Infect 2011; 17: 1366–1371
10.1111/j.1469-0691.2010.03402.x
Corresponding author: J. Garbino, University Hospitals Geneva,
Infectious Diseases, 24 Rue Micheli du crest, 1211 Geneva, Switzerland
E-mail: jgarbino@bluewin.ch
Introduction
Invasive aspergillosis (IA) is an opportunistic infection that
occurs mainly among patients with haematological malignan-
cies, most notably during prolonged periods of neutropenia
[1–4]. In recent years, however, IA has increasingly been rec-
ognized as an emerging disease of non-neutropenic patients
[5–10]. Underlying conditions have included obstructive pul-
monary disease or connective tissue diseases requiring corti-
costeroid therapy, liver cirrhosis, and solid cancer with and
without treatment. Many of the affected patients needed
intensive care. IA was often not suspected, and diagnosed
late or at autopsy [6,11,12]. Mortality rates >80% have been
reported. A high level of suspicion is needed to allow for
early diagnosis and timely therapeutic intervention. A better
understanding of the population at risk and the spectrum of
diseases caused by IA in non-haematological patients may
contribute to improving the outcome of this potentially
treatable disease. Therefore, we conducted a nationwide
study to analyse documented cases of aspergillosis in non-
neutropenic patients at ﬁve Swiss university hospitals.
Methods
Patient population and data collection
We conducted a retrospective observational analysis of all
aspergillosis cases in non-neutropenic patients diagnosed at
the ﬁve Swiss university hospitals collaborating in the fungal
network of Switzerland (FUNGINOS) between 1 January
2004 and 31 December 2005.
Patient identiﬁcation was based on comprehensive screen-
ing of hospital records, infectious diseases consultants’ notes,
all types of microbiology laboratory results, radiology
reports, and pharmacy records on antifungal drugs with
activity against Aspergillus spp.
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We excluded patients with current or past neutropenia
(deﬁned as neutrophil counts <500/lL for >10 days), hae-
matopoietic stem cell transplantation (HSCT), and leukaemia.
Data were extracted from patient’s charts as well as
microbiology, pathology and radiology reports. Case report
forms were subjected to the scrutiny of a data review com-
mittee before being entered into a database.
Hospital statistics for the years 2004 and 2005 (number of
patient beds, admissions, and patient-days) were collected at
all ﬁve university hospitals.
Case deﬁnition
Diagnosis of invasive disease was based on the case deﬁni-
tion by the European Organization for Research and Treat-
ment of Cancer/Mycoses Study Group [13], with the
following modiﬁcations: the restriction to patients with can-
cer and recipients of HSCT was lifted to include all patient
groups (allowing for inclusion of patients with no recognized
predisposing host factors); and galactomannan in serum,
bronchoalveolar lavage ﬂuid, and cerebrospinal ﬂuid, as well
as detection of Aspergillus spp. in clinical specimens by PCR.
Patients with histological evidence of mould infection and
negative cultures were only included when Aspergillus was
conﬁrmed as the causative pathogen by PCR [14].
Only proven/probable cases of IA were enrolled in the
study.
The diagnosis of disseminated IA required the demonstra-
tion of Aspergillus sp. at two or more non-contiguous sites
[15,16].
Diagnosis of subacute and chronic pulmonary aspergillosis
was based on deﬁnitions proposed by Segal et al. [17] and
Denning et al. [18], respectively.
Invasive Aspergillus rhinosinusitis was diagnosed in symp-
tomatic patients with opaciﬁed sinuses and tissue invasion
outside the eroded bony walls of the sinuses on imaging
studies and/or by histological demonstration of tissue inva-
sion by moulds conﬁrmed as Aspergillus spp. by either culture
or PCR [15,16].
Corticosteroid treatment was deﬁned as exposure to
‡10 mg/day prednisone equivalent for ‡30 days. Immunosup-
pression refers to exposure to other immunosuppressive
drugs (e.g. azathioprine, mycophenolate, tacrolimus, and inf-
liximab) that did not induce neutropenia for ‡9 days.
Statistical analysis
Basic demographic characteristics, comorbidities, laboratory
parameters and treatment modality of IA were compared
with the chi-square test and Fisher’s exact test for categori-
cal variables, and the Mann–Whitney test for continuous
variables. Logistic regression was used to estimate the ORs
of post-mortem diagnosis of pulmonary IA. We built the ﬁnal
multivariate model with a forward stepwise approach, adding
in the model, one by one, each factor signiﬁcant at the level
of 0.1 in the univariate analysis and other factors deﬁned in
the literature as prognostic. A p-value of 0.05 for two-tailed
tests was set as the cut-off for signiﬁcance. All analyses were
performed with STATA software version 9.2 for Windows
(StataCorp, College Station, TX, USA).
Results
A total of 76 patients were enrolled during the 2-year study
period.
Nine patients were excluded from the analysis. The rea-
sons for exclusion by the data review committee were lack
of evidence of invasive disease in eight cases of sinus asper-
gilloma and disease occurrence outside of the study time
frame in one patient. Thus, the analysed study population
comprised 67 cases with proven/probable IA. In 2004–2005,
353 741 patients were admitted to the 4079 patient beds
(medical, surgical, paediatric wards, and intensive-care unit
(ICU)) at the ﬁve university hospitals (430 ICU beds with
65 152 admissions).
Invasive pulmonary aspergillosis (IPA) was diagnosed in 42
of 67 (63%) of patients: 30 of 42 (72%) cases were proven,
and 12 (28%) were probable cases (Table 1). In seven of 42
patients (17%), aspergillosis had spread from the lungs to at
least one other organ (brain, kidney, heart, eye, peritoneum,
bone, and skin); in the others, only pulmonary disease was
diagnosed. Invasive extrapulmonary aspergillosis without a
detectable pulmonary focus was found in ten of 67 (15%)
patients. In two patients, direct inoculation into the skin and
bone was the most likely route of infection. Interestingly, in
six patients with central nervous system aspergillosis, neither
the lungs nor the sinuses, the most likely portals of entry,
showed any signs of disease. Invasive rhinosinusitis did not
give rise to disseminated disease in any patient. Subacute and
TABLE 1. Manifestations of invasive aspergillosis in non-neu-
tropenic hosts
Invasive pulmonary aspergillosis 42
Localized disease 35
Disseminated disease 7
Invasive extrapulmonary aspergillosisa 10
Invasive rhinosinusitis 6
Subacute pulmonary aspergillosis 3
Chronic pulmonary aspergillosis 6
Total 67
aCentral nervous system (n = 7), bone (n = 2), skin (n = 1).
In addition, there were 21 patients with pulmonary aspergilloma and 40 patients
with sinus aspergilloma.
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chronic pulmonary aspergillosis was diagnosed in nine of 67
(13%) patients.
Further analysis was focused on the patients with IPA.
Their median age was 60 years (interquartile range 51–66)
and 32 (76%) were male. Their underlying diseases and risk
factors for IA are shown in Table. 2. Chronic lung disease,
cancer and solid organ transplantation were the most com-
mon underlying diseases. The majority of patients had
received prednisone or another immunosuppressive regimen.
The median level of C-reactive protein was 61 UI (interquar-
tile range 5–183). Twenty-ﬁve patients were given antifungal
treatment, which was combined with surgery in ten. Three
patients were treated with surgery alone; none of them died.
The mortality rate among patients who received antifungal
treatment was 35% (eight of 23 died) The median time to
death was 40 days (interquartile range 12–91). In 16 of 42
(38%) patients, the diagnosis of IPA was only established
after death; 15 of them (94%) did not receive antifungal
treatment with activity against Aspergillus. Overall, the mor-
tality rate reached 57.1%.
Among non-neutropenic patients admitted to a university
hospital in Switzerland, we found an incidence of IPA of 1.2
per 10 000 admissions. The incidence rate for patients
admitted to the ICU was 2.8 (18 per 65 152).
To elucidate why the diagnosis of IPA is often missed dur-
ing the patient’s life, a risk factor analysis was performed. In
univariate analysis, only higher age was signiﬁcantly associated
with post-mortem diagnosis (OR 2.1; 95% CI 1.1–4.2;,
p 0.034). The results of the multivariate analysis are shown
in Table 3. After adjustment for age, history of chronic lung
disease, solid organ transplantation or previous corticoste-
roid treatment, and C-reactive protein, older age remained a
signiﬁcant risk factor for post-mortem diagnosis of IA. In
contrast, solid organ transplantation and chronic lung disease
were independently associated with lower odds of post-mor-
tem diagnosis (Table 4).
Diagnostic tools and imaging
The pathology report was the diagnostic tool that permitted
identiﬁcation of the largest number of patients: 48 of 67
(72%). It was based on biopsies in 29 (43.3%) cases and on
autopsy in 19 (28.4%). Sixteen of the autopsy cases had IPA.
A chest X-ray was available for 48 of 51 (94%) patients
with IPA, and abnormal ﬁndings were present in 42 (87.5%).
A chest computed tomography (CT) scan was available for
37 of 51 (72.5%) of the patients with IPA, and was consid-
ered to be abnormal in 35 (94.6%).
Discussion
A number of recent reports of case series and single-centre
cohorts document the expansion of the at-risk population
TABLE 2. General characteristics of patients with invasive
pulmonary aspergillosis (n = 42)
Characteristic n %
Age (median, IQR) 60 51–66
Male gender 32 76.2
Cancer 13 31.0
Transplantation 13 31.0
Chronic lung disease 20 47.6
Chemotherapy 3 7.1
ICU stay 18 42.9
Mechanical ventilation 14 33.3
Prednisone 24 57.1
Immunosuppression 11 26.2
CRP (mg/mL) (median, IQR) 61.5 5–183
Post-mortem IA diagnosis 16 38.1
Outcome: treatment failure 29 60.0
Death 24 57.1
Time to death (if ante-mortem
diagnosis), days (median, IQR)
40 12–91
CRP, C-reactive protein; IA, invasive aspergillosis; ICU, intensive-care unit; IQR,
interquartile range.
TABLE 3. Risk factors and univari-
ate ORs of post-mortem diagnosis
of pulmonary invasive aspergillosis







OR 95% CI p-valuen % n %
Age (median, IQR) 65 57–71 58 48–63 2.1a 1.1–4.2 0.034
Male gender 13 81.3 19 73.1 0.6 0.1–2.9 0.548
Cancer 7 43.8 6 23.1 2.6 0.7–9.9 0.165
Transplantation 3 18.8 10 38.5 0.4 0.1–1.6 0.188
Chronic lung disease 5 31.3 15 57.7 0.3 0.1–1.2 0.101
ICU stay 6 37.5 12 46.2 0.7 0.2–2.5 0.583
Mechanical ventilation 6 37.5 8 30.8 1.4 0.4–5.0 0.654
Prednisone 12 75.0 12 46.2 3.5 0.9–13.8 0.073
Immunosuppression 4 25.0 7 26.9 0.9 0.2–3.8 0.891
CRP (mg/lL)
(median, IQR)
74 22–187 20 0–183 1.0b 0.9–1.1 0.340
CRP, C-reactive protein; ICU, intensive-care unit; IQR, interquartile range.
aPer 10 years older
bPer 10 mg/mL increase in CRP.
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for IA beyond the traditionally recognized risk groups to
include patients with chronic obstructive pulmonary disease
(COPD) (commonly receiving corticosteroid treatment and
often admitted to the ICU), critically ill patients with pro-
longed corticosteroid treatment for reasons other than
obstructive lung disease, and patients with decompensated
hepatic cirrhosis [6,10,19–26]. Indeed, IA among patients
with non-haematological diseases may be more common in
certain centres than among those with haematological dis-
eases known to be risk factors. Exacerbated COPD was the
underlying disease in more than one-half of 53 patients with
IPA seen at a single institution [10]. In addition, patients with
haematological diseases accounted for minorities of 41%,
36% and 34% of three cohorts with proven/probable IA
admitted to the ICU [6,12,22]. Corticosteroid treatment,
mostly for exacerbated COPD, was the dominant underlying
factor in these three cohorts.
Most reports of the past few years have focused on IA in
particular risk groups, i.e. patients with COPD or critically ill
patients admitted to the ICU, and were commonly con-
ducted at a single centre. The present study, in contrast, was
conducted countrywide at all ﬁve teaching hospitals, and
enrolled all non-neutropenic patients irrespective of the nat-
ure of their risk. Over the 2-year study period, we identiﬁed
67 patients with proven or probable IA.
The lungs and sinuses, the portals of entry of airborne
Aspergillus conidia, were the sites of infection of 85% of
cases. IPA, the most common disease manifestation, was
found in 63%. Disseminated disease was detected in 17% of
patients with documented pulmonary foci of disease. In addi-
tion, in the absence of evidence of infection of the paranasal
sinuses, the six cases of apparently isolated cerebral aspergil-
losis must also represent disseminated disease. Primary pul-
monary or, much more rarely, gastrointestinal foci may have
been missed in imaging studies or at autopsy. Among 36
autopsied patients with COPD and IA, dissemination from
the lungs was described in 20% [23].
IA not involving the respiratory tract was rare. No
patient with primary gastrointestinal aspergillosis was identi-
ﬁed. Most of the cases with skin and bone disease were
caused by direct traumatic inoculation of fungal conidia.
The incidence of IPA in non-neutropenic patients of 1.2 per
10 000 hospital admissions found in Switzerland is similar
to the rate reported for a large Spanish teaching hospital
(1.1 per 10 000 admissions) [10]. The incidence among
patients admitted to the ICU of 2.8 cases per 10 000 ICU
admissions, however, is ten-fold inferior to the rate
reported for non-neutropenic patients from a single centre
in Belgium (28.5 per 10 000 ICU admissions) [22]. The
entry criterion of a respiratory specimen positive for
Aspergillus spp. in the Belgian study may account for this
difference.
The most prevalent underlying conditions for IPA in non-
neutropenic patients identiﬁed in this study were corticoste-
roid treatment (‡10 mg/day prednisone for ‡30 days) and
chronic lung disease. The European Organization for
Research and Treatment of Cancer/Mycoses Study Group
criteria list corticosteroid administration for more than
3 weeks as a predisposing host factor for IA, and, indeed,
steroids have been documented as risk factors for the devel-
opment of IA in the majority of critically ill patients as well
as those with COPD. Forty-three of 56 (77%) COPD
patients with IA reported in the literature up to 2005 were
receiving steroids at admission [23]. Among critically ill
patients without haematological malignancy, 87% of those
with proven IA and all of those with probable IA had been
given steroids [6]. In patients with underlying lung disease,
even low doses (£15 mg/day prednisone) of continuously
administered steroids are sufﬁcient for the development of
IA [19]. Although most patients with COPD, particularly
those with exacerbations severe enough to be treated by
mechanical ventilation, are given steroids, COPD alone, with-
out concomitant use of steroids, can be a risk factor for IA,
as documented by Cornillet et al. [8].
Steroid use may also explain the absence of fever observed
in as many as two-thirds of patients [10,23]. Together with the
milder symptoms of IA in non-neutropenic patients, particu-
larly with respect to cough and pleuritic chest pain, this may
explain why the correct diagnosis is often made late or at
autopsy, with grave consequences for outcome [8]. Indeed,
mortality rates exceeding 80% are consistently reported for
non-haematological patients [6,19,20]. A higher survival rate
of 28.3% has been recently been reported in COPD patients
with lower respiratory tract specimens positive for Aspergillus
spp. [10], which may have increased the clinicians’ awareness
of the possibility of IA. The mortality rate in this study reached
57.1%; only 62% of patients, however, received treatment
active against Aspergillus spp. In a worrisome 38% of our
patients who were not given antifungal drugs the diagnosis
TABLE 4. Multivariate ORs of post-mortem diagnosis of
pulmonary invasive aspergillosis in 42 non-neutropenic
patients
Variable ORa 95% CI p-value
Age, per 10 years older 3.16 1.08–9.21 0.035
Transplantation 0.02 0.01–0.37 0.009
Chronic lung disease 0.05 0.01–0.69 0.025
Prednisone 8.04 0.79–81.5 0.078
CRP, per 10 mg/mL increase 1.00 0.93–1.07 0.961
CRP, C-reactive protein.
aAdjusted for all variables listed in the table.
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was only made at autopsy. In a multivariate analysis, older age
was signiﬁcantly associated with the diagnosis of IA missed
during the patient’s lifetime. Solid organ transplantation and
chronic lung diseases, in contrast, lowered the odds of a post-
mortem diagnosis. These ﬁndings possibly reﬂect more aggres-
sive diagnosis and prompt commencement of antifungal ther-
apy in younger patients, who are known to be at higher risk of
invasive fungal disease.
If the diagnosis of IPA is considered at all, it is difﬁcult to
establish in a patient population in whom histopathological
examinations can often not be performed, where imaging
studies are of limited value, culture and microscopy of respi-
ratory samples have a sensitivity and speciﬁcity of approxi-
mately 50%, and the galactomannan assay in serum has a
substantially lower sensitivity than in neutropenic patients
[23,25]. Galactomannan detection in bronchoalveolar lavage
ﬂuid has recently been ascribed a sensitivity and speciﬁcity
for IA in critically ill patients approaching 90% [6]. If con-
ﬁrmed, this approach could substantially enhance our diag-
nostic capacity in these patients.
In addition, surveillance in the non-neutropenic population
must be emphasized, particularly in the presence of factors
associated with IA: corticosteroid therapy (even at low
doses), chronic respiratory diseases, and ICU admission, with
or without mechanical ventilation.
An important limitation of the study results from its ret-
rospective design and the rarity of some disease manifesta-
tions of IA except for IPA. We were unable to perform a
comparative analysis of the clinical presentation and risk pro-
ﬁles associated with individual manifestations of IA. This
might have been helpful to establish improved diagnostic
approaches. Considering the large proportion of cases diag-
nosed at autopsy and the declining autopsy rate at all the
participating clinics, it is conceivable that some cases may
have been missed and that the true incidence of IA in this
patient population may be higher. Nevertheless, by combin-
ing a wide range of search strategies, a remarkable number
of cases of IA in non-neutropenic patients were identiﬁed.
Inclusion of all forms of IA, careful review of cases by an
experienced data review committee and collaboration
between all university hospitals providing a countrywide sur-
vey are the strengths of the present study.
In conclusion, IA remains a major life-threatening infec-
tion. This 2-year survey at all ﬁve Swiss teaching hospitals
emphasizes the high frequency of IA in non-neutropenic
patients, its high mortality rate, and the high proportion of
post-mortem diagnosis. Clinical signs are frequently lacking
in mildly immunosuppressed patients, but recent major
advances in the diagnosis of IPA may aid in identifying
affected patients. Conditions that should increase the level
of suspicion of IPA include corticosteroid therapy, chronic
lung disease, and ICU stay with or without mechanical
ventilation.
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